4D Molecular Therapeutics Partners with Otsuka for APAC Market

4D Molecular Therapeutics ( (FDMT) ) has shared an announcement.

On October 31, 2025, 4D Molecular Therapeutics entered into a collaboration agreement with Otsuka Pharmaceutical, granting Otsuka exclusive rights to develop and commercialize 4D-150 for ophthalmological diseases in the Asia-Pacific region. This agreement includes an upfront payment of $85 million and potential milestone payments, with both companies sharing development costs. The collaboration is expected to enhance 4D Molecular Therapeutics’ market presence in the APAC region while retaining rights outside these territories, potentially impacting stakeholders positively through expanded market reach and financial gains.

The most recent analyst rating on (FDMT) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.

Spark’s Take on FDMT Stock

According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.

The overall stock score is primarily influenced by the company’s financial performance challenges, which are typical for early-stage biotech firms. Despite these challenges, the stock shows strong technical momentum, suggesting positive market sentiment. However, the lack of profitability and absence of dividends weigh down the valuation score.

To see Spark’s full report on FDMT stock, click here.

More about 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. operates in the biotechnology industry, focusing on developing gene therapy products for ophthalmological diseases. The company is known for its innovative approach to treating conditions like wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

Average Trading Volume: 1,319,874

Technical Sentiment Signal: Buy

Current Market Cap: $528.7M

Find detailed analytics on FDMT stock on TipRanks’ Stock Analysis page.